Sex-Differences in Alpha-1 Antitrypsin Deficiency: Data From the EARCO Registry.

Alpha1-antitrypsin Alpha1-antitrypsin deficiency Chronic obstructive pulmonary disease Gender

Journal

Archivos de bronconeumologia
ISSN: 1579-2129
Titre abrégé: Arch Bronconeumol
Pays: Spain
ID NLM: 0354720

Informations de publication

Date de publication:
09 Jul 2024
Historique:
received: 16 05 2024
revised: 19 06 2024
accepted: 20 06 2024
medline: 28 7 2024
pubmed: 28 7 2024
entrez: 27 7 2024
Statut: aheadofprint

Résumé

Sex and gender influence many aspects of chronic obstructive pulmonary disease (COPD). Limited data are available on this topic in alpha-1 antitrypsin deficiency (AATD). We therefore aimed to investigate sex issues in the EARCO registry, a prospective, international, observational cohort study. Baseline data from PiZZ individuals, enrolled in the registry with complete data on sex and smoking history were analysed by group comparisons and binary logistic regression analyses. 1283 patients with AATD, 49.3% women were analysed. Females reported less tobacco consumption (16.8±12.2 vs. 19.6±14.5 PY, p=0.006), occupational exposures towards gases, dusts or asbestos (p<0.005 each) and consumed less alcohol (5.5±7.6 vs. 8.4±10.3u/week, p<0.001). Females reported COPD (41% vs. 57%, p<0.001) and liver disease (11% vs. 20%, p<0.001) less often. However, they had a higher prevalence of bronchiectasis (24% vs. 13%, p<0.001). Despite better lung function (FEV Men had higher rates of COPD and liver disease, women were more likely to have bronchiectasis. Women's higher symptom burden and exacerbation frequency suggest they may need tailored treatment approaches.

Sections du résumé

BACKGROUND BACKGROUND
Sex and gender influence many aspects of chronic obstructive pulmonary disease (COPD). Limited data are available on this topic in alpha-1 antitrypsin deficiency (AATD). We therefore aimed to investigate sex issues in the EARCO registry, a prospective, international, observational cohort study.
METHODS METHODS
Baseline data from PiZZ individuals, enrolled in the registry with complete data on sex and smoking history were analysed by group comparisons and binary logistic regression analyses.
RESULTS RESULTS
1283 patients with AATD, 49.3% women were analysed. Females reported less tobacco consumption (16.8±12.2 vs. 19.6±14.5 PY, p=0.006), occupational exposures towards gases, dusts or asbestos (p<0.005 each) and consumed less alcohol (5.5±7.6 vs. 8.4±10.3u/week, p<0.001). Females reported COPD (41% vs. 57%, p<0.001) and liver disease (11% vs. 20%, p<0.001) less often. However, they had a higher prevalence of bronchiectasis (24% vs. 13%, p<0.001). Despite better lung function (FEV
CONCLUSION CONCLUSIONS
Men had higher rates of COPD and liver disease, women were more likely to have bronchiectasis. Women's higher symptom burden and exacerbation frequency suggest they may need tailored treatment approaches.

Identifiants

DOI: 10.1016/j.arbres.2024.06.019 PMID: 39068055
pubmed: 39068055
pii: S0300-2896(24)00244-8
doi: 10.1016/j.arbres.2024.06.019
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Hilal Ersöz (H)

Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany.

María Torres-Durán (M)

Pneumology Service Hospital Alvaro Cunqueiro, Vigo, Institute for Health Research Galicia Sur (IISGS), Vigo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Alice M Turner (AM)

Institute for Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Hanan Tanash (H)

Department of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University, Malmö, Sweden.

Carlota Rodríguez García (CR)

Department of Pulmonology, Hospital Clínico-Universitario de Santiago, Santiago de Compostela, Spain; Interdisciplinary Research Group in Pulmonology, Institute of Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

Angelo Guido Corsico (AG)

Department of Internal Medicine and Therapeutics, University of Pavia, Italy; Respiratory Diseases Division, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

José Luis López-Campos (JL)

Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Marc Miravitlles (M)

Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus - Health Care Provider of the European Reference Network on Rare Respiratory Diseases (ERN LUNG), Barcelona, Spain.

Christian F Clarenbach (CF)

Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Kenneth R Chapman (KR)

University of Toronto, Toronto, Canada.

Jose Mª Hernández Pérez (JMH)

Pneumology Department, Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz de Tenerife, Spain.

Catarina Guimarães (C)

Pulmonology Department,Hospital Senhora da Oliveira, Guimarães, Portugal.

Eva Bartošovská (E)

Thomayer hospital, Charles University, Prague, Czech Republic.

Timm Greulich (T)

University Medical Centre Giessen and Marburg, Philipps-University, Deparment of Medicine, Pulmonary and Critical Care Medicine, Member of the German Centre for Lung Research (DZL), Marburg, Germany.

Miriam Barrecheguren (M)

Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus - Health Care Provider of the European Reference Network on Rare Respiratory Diseases (ERN LUNG), Barcelona, Spain.

Andreas Rembert Koczulla (AR)

Pneumologische Rehabilitation, Deutsches Zentrum für Lungenforschung, Philipps-Universität Marburg, Marburg, Germany; Schön Klinik Berchtesgadener, PMU Salzburg, Austria.

Philipp Höger (P)

Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany.

Arturo Olivares Rivera (AO)

Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany.

Felix Herth (F)

Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany.

Franziska C Trudzinski (FC)

Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: franziska.trudzinski@med.uni-heidelberg.de.

Classifications MeSH